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Background: Cystic fibrosis (CF) is a recessively inherited condition caused by mutation of the CFTR gene. Newborn infants with CF have
raised levels of immuno-reactive trypsinogen (IRT) in their serum. Measurement of IRT in the first week of life has enabled CF to be
incorporated into existing newborn screening (NBS) blood spot protocols. However, IRT is not a specific test for CF and NBS therefore
requires a further tier of tests to avoid unnecessary referral for diagnostic testing. Following identification of the CFTR gene, DNA analysis
for common CF-associated mutations has been increasingly used as a second tier test. The aim of this study was to survey the current practice
of CF NBS programmes in Europe.
Method: A questionnaire was sent to 26 regional and national CF NBS programmes in Europe.
Results: All programmes responded. The programmes varied in number of infants screened and in the protocols employed, ranging from
sweat testing all infants with a raised first IRT to protocols with up to four tiers of testing. Three different assays for IRT were used; in the
majority (24) this was a commercially available kit (Delfia™). A number of programmes employed a second IRT measurement in the 4th
week of life (as the IRT is more specific at this point). Nineteen programmes used DNA analysis for common CFTR mutations on samples
with a raised first IRT. Three programmes used a second IRT measurement on infants with just one recognised mutation to reduce the number
of infants referred for sweat testing. Referral to clinical services was prompt and diagnosis was confirmed by sweat testing, even in infants
with two recognised mutations in most programmes. Subsequent clinical pathways were less uniform. Multivariate analysis demonstrated a
relationship between the age of diagnosis and the timing of the first IRT. More sweat tests were undertaken if the first IRT was earlier and the
diagnosis was later.
Conclusions: Annually these programmes screen approximately 1,600,000 newborns for CF and over 400 affected infants are recognised.
The findings of this survey will guide the development of European evidence based guidelines and may help new regions or nations in the
development and implementation of NBS for cystic fibrosis.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Neonatal screening; Europe; IRT; Diagnosis1. Introduction
Cystic fibrosis (CF) is caused by mutation of the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR)
gene [1]. In parts of Europe, the incidence can be as high
as 1 in every 1000 births with Caucasians affected more
frequently than other ethnic groups [2]. The heteroge-
neous nature of the condition to some extent reflects the
large number of mutations that can affect the CFTR gene
and the impact of other gene modifiers [3]. With the
“classic” severe phenotype, outlook without treatment is
poor with death frequently occurring in the first decade of
life [4]. Prognosis has improved significantly with early
and active treatment of chest infection and an holistic
approach to management with particular attention to nu-
tritional well being [5]. However, even with modern treat-
ment regimens death during childhood is still occasionally
reported [6,7].
Infants with a “severe” phenotype often have a short
asymptomatic neonatal period and recognition in the 1970s
that CF infants have high serum immunoreactive trypsino-
gen (IRT) levels, prompted the suggestion that CF may be asuitable condition for newborn screening (NBS) [8]. A raised
IRT in the first week of life is a sensitive test for CF but not
specific and a second “tier” of testing avoids an inappropriate
number of families presenting to clinical services for
definitive diagnostic testing [9,10]. In early protocols, the
second tier involved repeating the IRT measurement at 3–
4 weeks when a raised level is more specific for the condition
[10]. A second tier by DNA analysis has become more
widely used since recognition of the CFTR gene in 1989.
Advantages of DNA analysis are that it can be undertaken on
the original blood spot sample and provides a specific result
with the recognition of two CF causing mutations [11–13]. A
potential disadvantage of DNA analysis is carrier recognition
[14,15]. Increased sweat chloride concentration remains an
important diagnostic marker of CF, particularly when
preliminary DNA analysis is negative or not fully informa-
tive, and sweat testing is an integral component of CF
newborn screening [16].
The European CF Society has established a Working
Group to examine and co-ordinate newborn screening for CF
across Europe. Objectives include mapping the current
situation, producing guidelines on critical issues and
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experts from various European countries have been invited
to take part in this project. In order to achieve a
comprehensive picture of the situation in Europe, a
questionnaire was circulated to European CF NBS pro-
grammes to survey current practice.
2. Materials and methods
The questionnaire was developed by a focus group and
divided into sections (Fig. 1): screening protocol, sample
collection (who collects and how, collection day), immuno-
reactive trypsinogen (levels, centiles, when tested, how
tested), genetic analysis (what mutations, techniques,Fig. 1. Questioinformed consent issues), sweat test (suggested age, positive
and borderline values, techniques), diagnosis (diagnostic
criteria, communication to the family), follow-up (clinical
protocols, segregation issues), data storing (informatics
tools, card storage), epidemiology (numbers of screened
newborns, identified CF cases, carriers, false positives, false
negatives). Aside from false negatives respondents were
asked to reflect on their current practice.
The questionnaire was sent to all established CF NBS
programmes in Europe known to the focus group. CF
physicians and societies in all European countries were
approached to achieve as complete an inclusion of
programmes as possible. Recipients were contacted and
encouraged to complete the questionnaire.nnaire.
Fig. 1 (continued).
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reported as median, with interquartile ranges in brackets.
Univariate statistics results are not reported when less than
50% answers were obtained. Multivariate analysis takes into
account outliers.
3. Results
Twenty-six questionnaires were sent in 2004/2005 and all
were returned: 7 from the UK, 1 (nationwide) from France,
12 from Italy, 3 from Spain, 1 (nationwide) from Austria, 1
from Poland and 1 from the Czech republic (Table 1). Some
questions were not answered, either because they did not
apply to the programme or the data were not available to the
person completing the questionnaire.
3.1. Descriptive results
3.1.1. Programme size and performance
IRT measured from a blood spot sample taken during the
first week of life was the initial step of all programmes (IRT-
1). Subsequently, a wide variety of protocols were reported
ranging from moving directly to sweat testing infants with a
raised IRT-1 to protocols involving four steps (Table 1). Thenumber of infants screened ranged from 8000 to 800,000.
From these data, we could calculate that incidence ranges
from 1/2250 to 1/10,500 (Table 2).
These services have been working for an average of
10 years (range 9 months to 31 years), screen more than
1,600,000 newborns per year, and every year detect more
than 400 affected neonates with an overall median calculated
incidence of 1/3500 (Table 2). The median number of infants
screened each year was 30,000 (18,000–54,000), the median
number of raised IRT-1, 295 (148–825) and the median
number of sweat tests, 70 (20–129). Subsequently, the
median number of CF cases identified per year was 9 (5–14)
and carriers 17 (13–25). The median number of false neg-
atives reported was 2 (1–5), but only 15 programmes an-
wered the question. This number was dependent on both
duration of screening programme and the communication of
late diagnosis by clinical services. False negatives were
caused by IRT-1 below the cut-off in the majority of reports
(Table 3).
Median age at diagnosis was 37 days (32–50), with
significant difference between programmes (Table 2). There
were clear associations between age at diagnosis and timing
of IRT-1 and resampling IRT (IRT-2) cut-off (see multivar-
iate analysis).
Table 1
Description of NBS programmes included in survey
Area 2nd tier 3rd tier 4th tier Details
Two-tier protocols
I Liguria ST – –
Three-tier protocols
CZ Western Czech republic MUT ST – PS; started February 2005
UK Wales MUT ST –
UK Northern Ireland IRT-2 ST –
UK Leeds Halifax Jersey MUT IRT-2 ST –
I Emilia Romagna IRT-2 ST –
I Calabria IRT-2 ST MUT – PS; survey answers based on 10 months experience
I Sardinia ST MUT – PS; survey answers based on 9 months experience
I Lombardy MUT IRT-2 ST – IRT-2 if IRT-1>97.5° centile MUT if IRT-1>99° centile
I Marche MUT IRT-2 ST – PS; IRT-2 if IRT-1>97.5° centile MUT if IRT-1>99.8° centile
I Tuscany MP IRT-2 ST –
I Piedmont MUT IRT-2 ST – PS; IRT-2 if IRT-1>98.6° centile MUT if IRT-1>99.6° centile
I Lazio 1 IRT-2 ST MUT –
I Lazio 2, Umbria MUT IRT-2 ST –
I Western Sicily MUT IRT-2 ST –
A Austria IRT-2 ST –
SP Catalunya IRT-2 MUT ST – PS
SP Castilla-Leon IRT-2 MUT ST
SP Galice IRT-2 MUT ST – PS
Four-tier protocols
F France MUT IRT-2 ST IRT-2 if MUT-tive
PL Poland MUT IRT-2 ST PS 1999–2003; IRT-2 if MUT-tive
UK South Yorkshire East Midlands MUT IRT-2 ST IRT-2 if 1 mutation or IRT-1>99.9th centile
UK Scotland MUT IRT-2 ST IRT-2 if 1 mutation or no mutations and non-Caucasian
UK Northamptonshire MUT IRT-2 ST IRT-2 if 1 or no mutations
UK East Anglia MUT IRT-2 ST IRT-2 if 1 mutation or IRT-1>99.9th centile
I Veneto Trentino Alto-Adige MUT MP IRT-2 ST IRT-2 if MUT and MP-tive and IRT-1 twice the cutoff
1st tier is always IRT (IRT-1).
Abbreviations: IRT-2=IRT resampling; MUT=genetic analysis; MP=meconium proteins; ST=sweat test; NA=not available; PS=pilot study.
More than one test per tier is considered if tests are performed at the same time.
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In all but one programme, the CF NBS protocol was
integrated into the current blood spot screening programme
(median number of conditions screened, 4 (3–5)). Consent for
CF screening was reported in 11/26 programmes (written in
three). Four blood spots (4–6) were collected in most
programmes and approximately 1% of these samples were
inadequate (0.5–1.53). Blood spot samples were collected
from day 3 (3–5) to day 5 (4–7) and delivered promptly to the
screening laboratory in most cases (1–3 days) but in one
centre, this took longer than 6 days. In the majority of
programmes, nurses or midwives were responsible for ob-
taining blood spot samples. In three programmes, doctors were
responsible and in one, parents were given the opportunity to
obtain the sample themselves following simple instructions.
In programmes in which a second IRT sample (IRT-2) was
taken (programmes that did not use DNA analysis on the first
sample or IRT-2 to reduce number of sweat tests for infants
with one mutation recognised), the test was organised from
day 27 (21–28) to day 28 (27–30). Reasons given to parents
for a second heel prick blood sample were “more blood
needed to complete test” in 8 and “result unclear” in 2centres. One centre reported an inadequate sample. Clearer
information was given from 4 centres (“CF cannot be
excluded” or “IRT-1 elevated”).
3.1.3. Laboratory issues
In the majority of programmes [24], IRT measurement
was undertaken using the Delfia™ technique (heterogeneous
time resolved fluorometric assay). In 12 of these, an
automated version was used (Autodelfia™). Two centres
used a radio-labelled immunoassay (RIA) and two, an
enzyme-linked immunospecific assay (ELISA). The national
programme in France uses both the Delfia technique (12
laboratories) and RIA (11 laboratories). The cut-off for IRT-1
was set at 70 ng ml−1 (60–70) or above the centile of 99%
(99–99.5). In 18 programmes, the laboratory would
regularly review the IRT-1 cut-off by examining the
population mean and spread. The median cut-off for IRT-2
was 50 ng ml−1 (40–56). All laboratories employed an
internal quality control process, although nine were not
involved in external quality control. Eight programmes store
the blood spot card for an unlimited time, the remaining store
them for a median of 7.5 years (3.6–18.8).
Table 2















UK Wales 32,500 1/2700 <4
UK Northern Ireland 23,000 1/2850 4–6
UK Leeds Halifax Jersey 11,000 1/2750 3–6
I Emilia Romagna 33,000 1/4700 8–9
I Calabria 16,000 – 6–9
I Sardinia 14,000 – 17
I Lombardy 92,000 1/4600 3–5
I Marche 13,000 1/5200 8–9
I Tuscany 30,000 1/3500 6
I Piedmont 37,000 1/2650 6
I Lazio 1 28,500 1/3150 NA
I Lazio 2, Umbria 33,000 NA NA
I Western Sicily 20,000 1/2500 6
A Austria 80,000 1/3500 5–6
SP Catalunya 62,500 1/5700 7–10
SP Castilla-Leon 18,000 1/4000 3–12
SP Galice 21,000 1/10,500 4–5
Four-tier protocols
F France 800,000 1/4700 5
PL Poland 90,000 1/5000 4–6
UK South Yorkshire East Midlands 55,000 1/2450 NA
UK Scotland 54,000 1/2700 From 3
upwards
UK Northamptonshire 8000 1/2250 3–8
UK East Anglia 25,000 1/2800 3–6
I Veneto Trentino Alto-Adige 52,000 1/4150 3–6
⁎ Figures collected after the questionnaire circulation, not included in data
analysis.
Table 3
Combined results (presented as median and interquartile ranges)
Years of screening 7 (3.6–18.8)
Screened per year 30,000 (18,000–54,000)
IRT +ive per year 295 (148–825)
Sweat tests per year
(as part of programme)
70 (20–129)
Number of CF cases per year 9 (5–14)
Carriers per year 17 (13–25)
False negatives since start of programme 2 (1–5)
False negatives per year 0.3
False negatives reported? Yes: 15 (57.7%)
No: 5 (19.2%)
Not always: 2 (7.7%)
Causes of false negatives First IRT low: 17 (65.4%)
No mutations recognised: 1
(3.9%)
Second IRT low: 4 (15.4%)
Negative sweat test: 1 (3.9%)
62 K.W. Southern et al. / Journal of Cystic Fibrosis 6 (2007) 57–65Nineteen of the 26 programmes incorporated DNA
analysis as the second tier of the CF screening protocol.
Median number of mutations examined was 31 (30–31), in
most cases by oligonucleotide ligation assay (OLA) [14],
although a range of molecular biology techniques were used
(commercially available kits, Innogenetics™ (4) and Eluci-
gene™ (3); denaturing gradient gel electrophoresis (DGGE)
(1); in-house kit (5) and sequencing in one pilot study). It
was reported that these panels covered a median of 82%
(76.8–86.3) of CFTR mutations in the screened population.
3.1.4. Processing a positive screening result
The majority of centres reported that they would not
undertake a sweat test until day 28 (14–30) of life, but in
some infants as young as 1 week were referred. Eighteen
laboratories measured sweat chloride concentration, 3 mea-
sured conductivity, 3 measured both. Generally one labora-
tory undertook these measurements for each programme (1–
3) and the median number of sweat tests at each laboratory
was 300 (150–400) per year (including sweat tests not relatedto NBS). A collection of 55 mg (50–94) was the accepted
minimum weight of sweat in centres measuring chloride
concentration. A sweat chloride between 40 (30–40) and 60
(60–60) mmol l−1 was considered a borderline sweat chlo-
ride result (7 considered 30 to be the lower limit). In 13
programmes, a sweat test was undertaken even if two CF
associated mutations were recognised (in four, never, and in
six, sometimes). In cases where a diagnosis was uncertain
following sweat test a variety of strategies were reported
including no further action [2], repeat sweat test [6], extended
DNA analysis [7], clinical investigations (stool analysis for
malabsorption [6], chest radiograph [1], respiratory cultures
[6]) and nasal potential difference measurement [1]. A
positive diagnosis was communicated in person to the parents
and in most cases by a specialist in CF (in some cases by a
General Paediatrician [6] or a Geneticist [2]). All pro-
grammes that involved DNA analysis [19] informed families
of identification of carrier status and the majority of pro-
grammes [21] referred parents of identified CF infants for
genetic counselling.
Clinical referral following a positive screen was generally
the following day (0–2) and in most cases to a specialist CF
centre [22]. In 11 centres, this would involve an admission
for clinical evaluation. Eighteen centres provided informa-
tion regarding segregation, which was undertaken in 8/18
with separate days for clinic visits. Three centres had strict
inpatient segregation with separate rooms, face masks for
consultations and no mixing of patients.
3.2. Multivariate analysis
Age at diagnosis showed a significant inverse correlation
with the timing of IRT-1 (p<0.001, Fig. 2) and with the cut-off
value for IRT-2 (p<0.01, Fig. 3). A lower age at diagnosis was
also associated with DNA analysis as a second tier test
(p<0.015, Fig. 4) and use of external quality control for the
IRT assay (p<0.015, Fig. 5). A higher incidence of CF
Fig. 2. Relationship between time to diagnosis and day on which IRT-1 is
taken.
Fig. 4. Relationship between the time to diagnosis and the incorporation of
DNA analysis into the second tier of testing.
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IRT-1 (p<0.03) and a lower cut-off for IRT-2 (p<0.02).
4. Discussion
This is the first detailed survey of NBS for CF in Europe.
The results demonstrate varied practice across the continent
with protocols ranging from a sweat test following raised
IRT-1 to those involving three or four tiers of testing. This
variability reflects a number of issues (1) the complexity of
NBS for CF, (2) geographical considerations, and (3) local
circumstances. For example, in a geographically small
region with limited molecular genetics and a good sweat
test service, there might be an argument to moving straight to
sweat test. However, in a geographically large region,
strategies to reduce the number of sweat tests (for example,
repeating the IRT on infants with one CFTR mutation
recognised) may be appropriate [17].
The aim of newborn screening is to recognise index cases
whilst causing minimal anxiety to the general public. This is
particularly pertinent to CF screening where the weight of
evidence that NBS improves long-term outcome is not as
clear as for other conditions such as phenylketonuria [18].
Early nutritional benefits from screening do not appear to be
maintained and a recent report suggested poorer chest
radiograph appearance in screened children associated with
an earlier acquisition of Pseudomonas aeruginosa lung
infection [19–21]. However, our expectations for infantsFig. 3. Relationship between time to diagnosis and the cut-off value set for
the resampling IRT (IRT-2).born with CF have changed over the past two decades and
the recent report of improved cognitive function in children
with better vitamin E levels at diagnosis is of particular
relevance [22,23]. In addition, NBS reduces the exposure of
families to what is often a long and stressful diagnostic
journey and gives couples the opportunity to make informed
reproductive decisions [24–26]. The general consensus is
that there is sufficient evidence to support NBS for CF and
following systematic review, the US Center for Disease
Control and Prevention concluded, “the health benefits to
children with CF outweigh the risk of harm and justify
screening for CF” [27]. Findings from this survey may aid
regions or countries in their development and implementa-
tion of NBS for CF.
The heterogeneous nature of CF means that there will
never be a perfect NBS protocol. Even incorporation of DNA
analysis into a protocol does not remove the often-
complicated clinical interface between the screening
programme and the eventual diagnosis. The majority of
programmes (over 70%) used DNA analysis as a second stepFig. 5. Relationship between time to diagnosis and the use of an IRT quality
assurance system.
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commonest CF causing mutation, phe508del, although in
most cases a panel of 31 mutations was employed. Evidence
from the screening programme in Massachusetts suggests
that increasing the number of mutations on the screening
panel does not necessarily improve case recognition but does
result in increased carrier recognition [15]. However, in areas
with a low frequency of phe508del (for example, South
Italy), these data may not apply. Individual areas need to
assess the implication of restricting the number of mutations
that are included in the second tier panel on case recognition.
In one programme CFTR gene sequencing was used, but
only as a pilot study. It is difficult to envisage that this could
represent a practical option for new programmes with
available technology. Carrier recognition is a potential
source of stress to families [14,28]. All centres employing
DNA analysis reported carrier status to families.
It is clear that NBS for CF can be incorporated into
ongoing NBS programmes although a significant frequency
of inadequate samples was reported (median 1%). How these
repeat samples are processed was not determined and it is not
clear from this survey what increase in inadequate samples
results from adding CF NBS to an existing programme. IRT
analysis requires a better quality of blood spot sample than
conventional NBS tests for phenylketonuria and congenital
hypothyroidism and training in this area is imperative for
regions implementing NBS for CF. In the majority of
programmes, blood spot samples were collected by mid-
wives or nurses. A second IRT sample was taken in the
fourth week of life in programmes without DNA analysis or
in some programmes with DNA analysis to reduce the
number of sweat test requests on infants with only one CFTR
mutation recognised (families of infants with one mutation
and IRT-2 below the cut-off are given information regarding
the carrier status and the low risk for CF). IRTwas generally
measured using the Delfia™ or Autodelfia™ techniques,
with a median cut-off of 70 ng ml−1 for IRT-1 and 50 ng
ml−1 for IRT-2. Most programmes reported using the top 1 or
0.5% of infants for the IRT-1 cut-off, adjusting this figure by
continuously monitoring the population mean for the
laboratory. All laboratories used internal quality control,
but the present lack of a robust external quality control is
highlighted by the fact that nine programmes were not
involved in any form of external quality assurance scheme
[29].
Sweat testing is a key component of the NBS protocols
for CF. In the majority of programmes, a sweat test was
undertaken even if two CF associated mutations were
recognised. The identification of a physiological abnormality
not only supports the molecular genetics but may also help
the family come to terms with this diagnosis. A sweat
chloride of 40–60 mmol l−1 was considered equivocal in
most centres, although 30 was the lower limit in seven. There
were a variety of responses as to how these infants should be
subsequently investigated. The majority of programmes
reported that sweat tests were being undertaken in one centreonly; however, in geographically diverse regions this may
not be possible and strategies to reduce sweat test numbers
(such as a second IRTwhen one mutation is recognised) may
be valid. The Association of Clinical Biochemists in the UK
recently produced a consensus document recommending that
50 sweat tests was the minimum a centre should be
undertaking in a year to maintain minimal experience to
achieve adequate standards (http://www.acb.org.uk/site/
guidelines.asp). Most centres continue to measure sweat
chloride concentration (considered the “gold standard” [30])
however obsolete apparatus for the filter paper method of
sweat collection may require centres to switch to capillary
methods of sweat collection.
It is imperative that regions developing NBS for CF have
clearly defined clinical referral pathways to maximise the
positive impact of screening and minimise negative out-
comes. Clear clinical referral pathways were evident in some
programmes, most often through CF specialist services. It
was not clear from the responses to these questionnaires that
such pathways were always in place; however, this may
reflect the fact that respondents were generally based in the
screening labs and not in CF clinics. However, a key
component of NBS for CF is the interface between the
positive result and the subsequent specialist care that these
infants need. It is evident from this survey that clear
pathways are needed with respect to processing a positive
result.
The programmes recorded in this survey cover geograph-
ically distinct regions with differing gene frequencies,
making comparison of performance inappropriate. In
addition, the programmes range in size from large national
to small regional and whilst some are well established, others
are in a pilot stage of development. However, some
conclusions can be drawn regarding factors that might
impact on performance, as determined by the average age of
diagnosis. Some clear relationships are evident from
multivariate analysis, most notably that an earlier collection
of IRT-1 is associated with an older age of diagnosis. It is
difficult to ascribe cause and effect to these relationships,
which may reflect the underlying medical system and
geographical variables. However, the higher incidence of
CF in areas with earlier IRT-1 measurements merits further
investigation. This relationship is supported by the finding
that earlier IRT-1 is associated with an increased number of
sweat tests (possibly leading to some delay). This relation-
ship is maintained after removal of an outlier programme that
reported an average age at diagnosis of 4 months (Fig. 2) and
the French screening programme, which is the largest
reported and performs a high number of sweat tests. DNA
analysis as the second tier of testing was related to an earlier
age of diagnosis. Previous reports have suggested improved
screening performance with DNA analysis, but there are no
randomised controlled trial data to support this [17,31].
This survey collected data from 26 programmes screening
approximately 1,600,000 newborns each year in Europe for
CF and identifying over 400 affected infants (a median
65K.W. Southern et al. / Journal of Cystic Fibrosis 6 (2007) 57–65incidence of approximately 1 in 3500). Significant variation
in NBS protocols exists, to some degree reflecting significant
geographical differences. As the evidence for NBS for CF
increases further regional and national programmes will
become established. These data may guide the implementa-
tion of such programmes and will form the basis of
consensus guidelines from the European CF Society
Working Group on newborn screening.
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